Navigation Links
New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting

promising pain response rate of 69% (based on a decrease of at least two points on a 10 point scale.)

Society of Nuclear Medicine Abstracts

Cytogen also reported today the presentation of a number of abstracts related to investigator-sponsored studies with QUADRAMET or Cytogen's monoclonal antibody-based molecular imaging agent for prostate cancer, PROSTASCINT(R) (capromab pendetide), at the 54th Annual Meeting of the Society of Nuclear Medicine taking place through June 6, 2007 in Washington, DC. The abstract titles and publication numbers are as follows:

"Combination of radionuclide therapy using Sm-153-Lexidronam and chemotherapy in patients with bone metastases of hormone refractory prostate cancer (HRPC): First results", by Nestle, et al. Saarland University Medical Center, Homburg/Saar, Germany (Abstract No. 127, Sunday, June 3, 2007, 5:03 PM)

"Radiation safety of outpatient therapy in patients receiving high-dose Sm-153 EDTMP treatment: A prospective study", by Bartosh et al., The University of Texas MD Anderson Cancer Center, Houston, Texas (Abstract No. 2027, Monday June 4, 2007, 1:42 PM)

"Comparison of animal biodistribution of EDTMP labeled with various beta emitting lanthanides", by Sohaib, et al., Pakistan Institute of Nuclear Sciences and Technology (PINSTECH), Islamabad, Pakistan (Abstract No. 461, Tuesday June 5, 2007, 3:18 PM)

"ProstaScint imaging - Reviewing the fundamentals", by Sureshbabu, et al., Excel Diagnostics Imaging Clinics, Houston, Texas (Abstract No. 2103, Monday June 4, 2007, 2:30 PM)

"Use of SPECT/CT in tumor localization: SPECT/CT versus planar and SPECT imaging in tumor localization" by Levi, et al. Florida Hospital College of Health Sciences, Orlando, Florida (Abstract No. 2228, Monday, June 4, 2007, 8:50 AM)

"Added value of SPECT-CT in patients explored by 111In-Capromab Pendetide (ProstaScint)", by Belhocine, et al. (Abstract No. 653, Wednesday June 6, 2007, 9:45 AM)


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
2. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
8. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
9. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
10. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data for Cytogen QUADRAMET Reported Annual ASCO Meeting
(Date:5/29/2015)... BOSTON , May 29, 2015 /PRNewswire/ ... custom automation, and contract manufacturing, and Vaxxas , ... drug delivery technology, have been named winners of the ... Nanopatch Jet Coating Instrument , an advanced technology platform ... development.  The award was announced last evening at the ...
(Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) and ... have entered into a clinical trial collaboration to evaluate ... immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... The planned study will assess the combination as a ... The Phase I study is expected to establish the ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
... U.S. Food and Drug Administration today advised consumers ... not to use the product. FDA warns that ... active pharmaceutical ingredient sibutramine, a prescription-only drug which ... the product label and could harm consumers, especially ...
... 8 Synapse Biomedical Inc ... U.S. Food and Drug Administration (FDA) designation of the ... Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis ( ... experiencing chronic hypoventilation and has now submitted for Humanitarian ...
Cached Medicine Technology:FDA: Potentially Harmful Stimulant Found in Slimming Beauty Capsules 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 3Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 4
(Date:5/29/2015)... 2015 A group of doctors have discovered ... national effort to teach this “new math” to children in ... been “sickened” by the recent implementation of Common Core Math ... it, Common Core is now a reality in children’s classrooms ... are now seeking ways to improve common core math training ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
(Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... is giving patients a long-lasting impression on what ... provider of VisitandCare.com is on a mission to revolutionize ... cosmetic dentistry with a high-class Wellness & Spa. ... of the world’s most successful medical tourism agencies ...
(Date:5/29/2015)... May 29, 2015 As spring has ... Metro series outdoor saunas have increased in popularity as ... and work at summer cottages. While a perennial ... in summer projects a few weeks earlier than usual. ... with smaller lot sizes tend to prefer the Patio ...
Breaking Medicine News(10 mins):Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... therapy (ECT) helps patients with severe depression who don't ... often in the earlier stages of the illness, ... ,"Electroconvulsive therapy has been shown to be ... persistent and severe depression, bipolar disorder, and schizophrenia," writes ...
... sudden outbreak of disease has claimed a tenth of Idahos ... fish food and labor. , The outbreak of ... in southwestern Idaho- the state Department of Fish and Game ... the region and official say that it probably resulted when ...
... Monday opposed introduction of sex education in Kashmir schools ... ,Addressing a media conference here, Asiya Andrabi, the DeM ... nefarious Indian designs to perpetuate obscenity and vulgarity in ... schools." ,Andrabi, branded as a hardliner, said ...
... in regard to doctor-patient ratio in various State Government ... varies from case to case depending upon various factors ... of patient-care required i.e. indoor/outdoor. According to the Medical ... works out to 1:1722. ,The patient ...
... company Advanced Cell Technology, is obviously thrilled with ... repair arteries and regenerate blood. , According to ... proceed on to hearts and arteries of ... have devised a straightforward way to make blood vessel precursor ...
... are 73557. There are 22273 numbers of doctors at ... on March 2006. As on 1.1.2007, total numbers of beds ... beds are available in urban government hospitals including Community Health ... of CHCs are located in government buildings. As on March ...
Cached Medicine News:Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2Health News:Disease Outbreak Claims Trout From Idaho Hatchery 2Health News:Hemangioblasts Aiding Eye Damage Repair 2
... Disc is a Hand Assisted Laparoscopic Surgery ... the surgeons hand may facilitate the procedure, ... has applications in colorectal, urological and general ... extracorporeal extension of pneumoperitoneum and abdominal access ...
... SleepStyle 200 series offers a range ... models. The design delivers therapy to ... features promote results in commercial and ... strongest differentiator in the SleepStyle 200 ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... S6 Lightweight II CPAP has sound ... that maintains consistent pressure. The backlit ... the settings easy, and the interface ... adjustments is simple. This CPAP device ...
Medicine Products: